Recent Clinical Successes in Liposomal Nanomedicines

Abstract

Review Recent Clinical Successes in Liposomal Nanomedicines Wenjie Gu , Gavin P. Andrews , and Yiwei Tian , * School of Pharmacy, Queen’s University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, UK. * Correspondence: y.tian@qub.ac.uk     Received: 19 December 2022 Accepted: 26 January 2023 Published: 3 February 2023   Abstract: The intrinsic limitations of cancer therapies promoted the development of safer liposomal nanocarriers capable of better distributing the payload away from normal tissues. Since then, liposomal nanocarriers have been considered the primary drug delivery system for many active pharmaceutical ingredients. These systems are now frequently investigated for the treatment of many infectious diseases. Along with the tremendous progress in the anticancer and antifungal liposomal nanomedicines, we have also gradually realised the difficulties associated with the existing liposomal nanocarrier designs. A better understanding of the nanocarrier-bio interactions may provide a new paradigm in liposomal nanocarrier design and better clinical endpoint efficacy. This short review focuses on the progress and benefits of two market-approved liposomal nanomedicines for cancer and fungal treatments.